Skip to main content
Qurient Co., Ltd. logo

Qurient Co., Ltd. — Investor Relations & Filings

Ticker · 115180 ISIN · KR7115180002 KO Professional, scientific and technical activities
Open in API
Filings indexed 437 across all filing types
Latest filing 2023-02-10 Major Shareholding Noti…
Country KR South Korea
Listing KO 115180

About Qurient Co., Ltd.

http://www.qurient.com/

Qurient Co., Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for unmet medical needs. The company operates on a proprietary 'Network R&D' model, a virtual approach that manages drug development programs from early discovery through clinical phases. Its pipeline includes Adrixetinib for chronic graft-versus-host disease (cGvHD), Telacebec for the treatment of tuberculosis, and a next-generation dual-payload Antibody-Drug Conjugate (ADC) platform for oncology. Qurient advances its portfolio through global clinical trials and strategic collaborations to address critical diseases.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. It details changes in share ownership by a major shareholder (Quad Investment Management Corp.) in the company Curient. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) as it tracks changes in significant ownership levels and insider/major shareholder holdings.
2023-02-10 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Large Shareholding' (주식등의 대량보유상황보고서) filed with the Financial Services Commission and the Korea Exchange. It details the shareholding changes of W Asset Management in the company Curient (큐리언트). This type of filing is specifically designed to notify the market when an entity's shareholding crosses significant thresholds (typically 5%), which corresponds to the 'Major Shareholding Notification' category.
2023-02-10 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Qurient) announcing a significant change (over 30%) in revenue or profit structure. This is a standard disclosure requirement in the Korean stock market (KRX) when financial results deviate significantly from the previous year. It provides key financial highlights (revenue, operating profit, net income) and the reasons for the change. Since this is an initial announcement of financial results rather than a full annual report or a transcript, it falls under the Earnings Release category. FY 2022
2023-02-10 Korean
기타시장안내(연구개발 우수기업 매출액 특례적용 관련)
Regulatory Filings Classification · 100% confidence The document is a short regulatory notice from the KOSDAQ market regarding a company's compliance with specific listing rules (revenue exemption for R&D-focused biotech companies). It does not constitute a full financial report, proxy, or earnings release, but rather a formal regulatory announcement regarding market status. As it does not fit into specific categories like M&A or dividends, it falls under the general regulatory filing category.
2023-02-07 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed by an executive (Chang Eyun Yu) of Qurient Co., Ltd. This is a standard regulatory filing in South Korea (DART system) used to disclose insider trading activities, specifically the acquisition of shares by a company director. This falls under the 'Director's Dealing' category.
2023-02-03 Korean
기타경영사항(자율공시)(다제내성결핵치료제 텔라세벡(Telacebec) 기술이전 계약체결)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (Qurient) announcing a technology transfer agreement (licensing deal) for a drug candidate (Telacebec). This type of corporate announcement regarding business development, licensing, or strategic partnerships falls under the 'Regulatory Filings' category as it does not fit into specific categories like M&A (which usually implies a takeover or merger) or other specialized financial reports.
2023-02-03 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.